Regulatory Topics-arkiv - Biosector Ltd.

Three Japanese quality inspectors examine a dented pharmaceutical carton in a clean quarantine area.

by Stefan Sandström

September 7, 2026

Successful Batch Release in Japan: The Essential Guide

Important disclaimer This article is a general primer. It is intended to give cross-functional teams a […]

0

Wooden blocks arranged in a clean bridge formation on a light table, labelled “Science & Innovation”, “Japanese Regulatory Pathway”, “Strategy · Partners · Evidence”, “Access & Reimbursement”, and “Patients in Japan”, illustrating the path from innovation to patient access in Japan.

by Stefan Sandström

August 31, 2026

ATMP and Regenerative Medicine in Japan: A Market Entry Guide for Overseas Developers

Japan is genuinely interesting for companies developing cell therapies, gene therapies and regenerative medicine product. But […]

0

An editorial infographic-style image, rendered in a highly detailed photorealistic illustration, shows multiple elevated railway tracks merging. One set of tracks, labeled with rusty signs for various local development milestones, curves into a main line labeled with a large overhead sign, 'GLOBAL DEVELOPMENT / MRCT (MULTI-REGIONAL CLINICAL TRIALS)'. Modern Japanese Shinkansen trains, including one with 'Phamaraxt' livery, travel on the main line. The scene is set in a daylight Yokohama cityscape, with skyscrapers and industrial buildings. Smaller rusty milestone signs date progress: 'DEC 2023 Phase I flexibility', 'OCT 2024 Rare-disease flexibility', 'JUN 2025 Clinical-trial reform', 'FEB 2026 One-stop service + PMDA', 'JUN 2026 Single IRB', and a final 'AUG 2026 Japan earlier in global development'. A main sign in the foreground left labels the converging tracks 'SEPARATE JAPANESE DEVELOPMENT'.

by Stefan Sandström

August 17, 2026

Clinical Trials in Japan: What Changed from December 2023 to August 2026

Japan changed important parts of its clinical development system in December 2023, when the Ministry of […]

0

Editorial illustration showing drug discovery evolving from primitive narrow target panels, through patient risk, toward modern mass spectrometry based off-target profiling and healthier treatment outcomes.

by Stefan Sandström

Modern Off-Target Profiling: The Murderous Reality Behind Clean Safety Panels

The Easy Hurdle That Kills Programs A drug candidate can clear the standard off-target panel and […]

0

Wide illustration showing Japan as an interconnected medical device market entry ecosystem, with nodes for PMDA and MHLW regulation, hospitals, reimbursement, distributors, manufacturing, digital health, and overseas investors.

by Stefan Sandström

Japan Medical Device Market Entry Strategy

Japan is no longer a market foreign medical device companies can afford to treat as “difficult […]

0

Editorial business illustration showing a giant wasp approaching a Takeda executive in a boardroom as dominoes labeled patent cliff, revenue erosion, cost savings, and workforce reduction begin to fall.

by Stefan Sandström

Takeda is Living the Japanese Proverb: “Wasp stings a crying eye”

The High Stakes of Innovation: Balancing Takeda’s $1.26B ‘Launch Machine’ and a $2.5B Antitrust Hit as […]

0

Editorial illustration showing complex healthcare data, regulatory, and localization inputs being streamlined through a Japan-themed gateway into clear eCOA/ePRO digital tools used by a doctor and patient.

by Stefan Sandström

Bringing eCOA and ePRO Solutions to Japan? What you Need to Get Right!

Japan is one of the world’s most demanding healthcare markets. It is also one of the […]

0

by Stefan Sandström

Infographic: Organoids and Organs-On-Chips

0

Illustration of a company at a crossroads choosing among three market access routes into Japan: Own MAH, 3rd party DMAH, or Japanese partner as MAH, shown as three numbered roads leading toward a Tokyo cityscape.

by Stefan Sandström

MAH, DMAH, or a Japanese Partner: A Strategic Choice You Need to Make Before Entering Japan

Entering Japan is not only about regulatory approval, launch planning, and commercial ambition. One of the […]

0

Abstract wide illustration showing Japan drug pricing from listing to post-launch revisions, using blue shapes on a sand background with red trigger markers.

by Stefan Sandström

December 15, 2025

Japan FY2026 Drug Pricing Reform Draft: What Changes at Listing, What Tightens After Launch

On December 12, 2025, Japan’s Ministry of Health, Labour and Welfare (MHLW) tabled a draft outline […]

0